申请人:Aquinox Pharmaceuticals (Canada) Inc.
公开号:US20160083387A1
公开(公告)日:2016-03-24
Compounds of formula (I): where R
1
, R
2
, R
3
, R
4a
, R
4b
, R
5
, R
6
and R
7
are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
本文描述了式(I)的化合物,其中R1、R2、R3、R4a、R4b、R5、R6和R7的定义如下,或其立体异构体或药学上可接受的盐。这些化合物具有SHIP1调节剂的活性,因此可用于治疗任何需要SHIP1调节的各种疾病、障碍或病况。本文还披露了包含式(I)的化合物与药学上可接受的载体或稀释剂的组合物,以及通过将这些化合物用于需要的动物的给药来进行SHIP1调节的方法。